{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T20:58:41Z","timestamp":1790456321312,"version":"4.1.0"},"reference-count":127,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T00:00:00Z","timestamp":1703203200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T00:00:00Z","timestamp":1703203200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s10875-023-01621-5","type":"journal-article","created":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T22:21:07Z","timestamp":1703197267000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Recent Insights in Pyrin Inflammasome Activation: Identifying Potential Novel Therapeutic Approaches in Pyrin-Associated Autoinflammatory Syndromes"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4527-6310","authenticated-orcid":false,"given":"Flore","family":"Wouters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Bogie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Wullaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"van der Hilst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,22]]},"reference":[{"key":"1621_CR1","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1146\/annurev-immunol-101220-030653","volume":"40","author":"C Ross","year":"2022","unstructured":"Ross C, Chan AH, von Pein JB, Maddugoda MP, Boucher D, Schroder K. Inflammatory caspases: toward a unified model for caspase activation by inflammasomes. Annu Rev Immunol. 2022;40:249\u201369.","journal-title":"Annu Rev Immunol."},{"key":"1621_CR2","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3389\/fimmu.2017.00253","volume":"8","author":"S \u00d6zen","year":"2017","unstructured":"\u00d6zen S, Batu ED, Demir S. Familial Mediterranean fever: recent developments in pathogenesis and new recommendations for management. Front Immunol. 2017;8:253.","journal-title":"Front Immunol."},{"key":"1621_CR3","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/JLB.3MIR0919-191R","volume":"107","author":"S Tartey","year":"2020","unstructured":"Tartey S, Kanneganti TD. Inflammasomes in the pathophysiology of autoinflammatory syndromes. J Leukoc Biol. 2020;107:379\u201391.","journal-title":"J Leukoc Biol."},{"key":"1621_CR4","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s40259-017-0224-7","volume":"31","author":"A Mistry","year":"2017","unstructured":"Mistry A, Savic S, van der Hilst JCH. Interleukin-1 blockade: an update on emerging indications. BioDrugs. 2017;31:207\u201321.","journal-title":"BioDrugs."},{"issue":"1","key":"1621_CR5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/ng0997-25","volume":"17","author":"French FMF Consortium","year":"1997","unstructured":"French FMF Consortium. A candidate gene for familial Mediterranean fever. Nat Genet. 1997;17(1):25\u201331. https:\/\/doi.org\/10.1038\/ng0997-25.","journal-title":"Nat Genet."},{"issue":"4","key":"1621_CR6","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/s0092-8674(00)80539-5","volume":"90","author":"The International FMF Consortium","year":"1997","unstructured":"The International FMF Consortium. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell. 1997;90(4):797\u2013807. https:\/\/doi.org\/10.1016\/s0092-8674(00)80539-5.","journal-title":"Cell"},{"key":"1621_CR7","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1182\/blood.V95.10.3223","volume":"95","author":"M Centola","year":"2000","unstructured":"Centola M, Wood G, Frucht DM, Galon J, Aringer M, Farrell C, et al. The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators. Blood. 2000;95:3223\u201331.","journal-title":"Blood."},{"key":"1621_CR8","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1182\/blood.V95.4.1451.004k52_1451_1455","volume":"95","author":"N Tidow","year":"2000","unstructured":"Tidow N, Chen X, M\u00fcller C, Kawano S, Gombart AF, Fischel-Ghodsian N, et al. Hematopoietic-specific expression of MEFV, the gene mutated in familial Mediterranean fever, and subcellular localization of its corresponding protein, pyrin. Blood. 2000;95:1451\u20135.","journal-title":"Blood."},{"key":"1621_CR9","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1093\/hmg\/11.8.961","volume":"11","author":"CA Wise","year":"2002","unstructured":"Wise CA, Gillum JD, Seidman CE, Lindor NM, Veile R, Bashiardes S, et al. Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Hum Mol Genet. 2002;11:961\u20139.","journal-title":"Hum Mol Genet."},{"issue":"21","key":"1621_CR10","doi-asserted-by":"publisher","first-page":"8087","DOI":"10.3390\/ijms21218087","volume":"21","author":"M Cornut","year":"2020","unstructured":"Cornut M, Bourdonnay E, Henry T. Transcriptional regulation of inflammasomes. Int J Mol Sci. 2020;21(21):8087. https:\/\/doi.org\/10.3390\/ijms21218087.","journal-title":"Int J Mol Sci."},{"key":"1621_CR11","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1182\/blood-2008-01-134932","volume":"112","author":"JJ Chae","year":"2008","unstructured":"Chae JJ, Wood G, Richard K, Jaffe H, Colburn NT, Masters SL, et al. The familial Mediterranean fever protein, pyrin, is cleaved by caspase-1 and activates NF-kappaB through its N-terminal fragment. Blood. 2008;112:1794\u2013803.","journal-title":"Blood."},{"key":"1621_CR12","doi-asserted-by":"publisher","first-page":"10819","DOI":"10.1038\/srep10819","volume":"5","author":"C Weinert","year":"2015","unstructured":"Weinert C, Morger D, Djekic A, Gr\u00fctter MG, Mittl PRE. Crystal structure of TRIM20 C-terminal coiled-coil\/B30.2 fragment: implications for the recognition of higher order oligomers. Sci Rep. 2015;5:10819.","journal-title":"Sci Rep."},{"key":"1621_CR13","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/sj.cdd.4401734","volume":"13","author":"JW Yu","year":"2006","unstructured":"Yu JW, Wu J, Zhang Z, Datta P, Ibrahimi I, Taniguchi S, et al. Cryopyrin and Pyrin activate caspase-1, but not NF-kappaB, via ASC oligomerization. Cell Death Differ. 2006;13:236\u201349.","journal-title":"Cell Death Differ."},{"key":"1621_CR14","doi-asserted-by":"publisher","first-page":"e3001351","DOI":"10.1371\/journal.pbio.3001351","volume":"20","author":"MSJ Mangan","year":"2022","unstructured":"Mangan MSJ, Gorki F, Krause K, Heinz A, Pankow A, Ebert T, et al. Transcriptional licensing is required for Pyrin inflammasome activation in human macrophages and bypassed by mutations causing familial Mediterranean fever. PLoS Biol. 2022;20:e3001351.","journal-title":"PLoS Biol."},{"key":"1621_CR15","doi-asserted-by":"publisher","first-page":"14384","DOI":"10.1073\/pnas.1613156113","volume":"113","author":"H Van Gorp","year":"2016","unstructured":"Van Gorp H, Saavedra PH, de Vasconcelos NM, Van Opdenbosch N, Vande Walle L, Matusiak M, et al. Familial Mediterranean fever mutations lift the obligatory requirement for microtubules in Pyrin inflammasome activation. Proceedings of the National Academy of Sciences. 2016;113:14384\u20139.","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"11","key":"1621_CR16","doi-asserted-by":"publisher","first-page":"e10547","DOI":"10.15252\/emmm.201910547","volume":"11","author":"F Magnotti","year":"2019","unstructured":"Magnotti F, Lefeuvre L, Benezech S, Malsot T, Waeckel L, Martin A, Kerever S, Chirita D, Desjonqueres M, Duquesne A, Gerfaud-Valentin M, Laurent A, S\u00e8ve P, Popoff MR, Walzer T, Belot A, Jamilloux Y, Henry T. Pyrin dephosphorylation is sufficient to trigger inflammasome activation in familial Mediterranean fever patients. EMBO Mol Med. 2019;11(11):e10547. https:\/\/doi.org\/10.15252\/emmm.201910547","journal-title":"EMBO Mol Med."},{"key":"1621_CR17","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nature13449","volume":"513","author":"H Xu","year":"2014","unstructured":"Xu H, Yang J, Gao W, Li L, Li P, Zhang L, et al. Innate immune sensing of bacterial modifications of Rho GTPases by the Pyrin inflammasome. Nature. 2014;513:237\u201341.","journal-title":"Nature."},{"key":"1621_CR18","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1124\/mol.115.097857","volume":"88","author":"OM Yu","year":"2015","unstructured":"Yu OM, Brown JH. G protein-coupled receptor and RhoA-stimulated transcriptional responses: links to inflammation, differentiation, and cell proliferation. Mol Pharmacol. 2015;88:171\u201380.","journal-title":"Mol Pharmacol."},{"key":"1621_CR19","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nrmicro2592","volume":"9","author":"K Aktories","year":"2011","unstructured":"Aktories K. Bacterial protein toxins that modify host regulatory GTPases. Nat Rev Microbiol. 2011;9:487\u201398.","journal-title":"Nat Rev Microbiol."},{"issue":"1","key":"1621_CR20","doi-asserted-by":"publisher","first-page":"e20190314","DOI":"10.1084\/jem.20190314","volume":"217","author":"AH Chan","year":"2020","unstructured":"Chan AH, Schroder K. Inflammasome signaling and regulation of interleukin-1 family cytokines. J Exp Med. 2020;217(1):e20190314. https:\/\/doi.org\/10.1084\/jem.20190314","journal-title":"J Exp Med."},{"key":"1621_CR21","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/ni.3457","volume":"17","author":"YH Park","year":"2016","unstructured":"Park YH, Wood G, Kastner DL, Chae JJ. Pyrin inflammasome activation and RhoA signaling in the autoinflammatory diseases FMF and HIDS. Nat Immunol. 2016;17:914\u201321.","journal-title":"Nat Immunol."},{"key":"1621_CR22","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.cbpa.2012.10.015","volume":"16","author":"EA Zverina","year":"2012","unstructured":"Zverina EA, Lamphear CL, Wright EN, Fierke CA. Recent advances in protein prenyltransferases: substrate identification, regulation, and disease interventions. Curr Opin Chem Biol. 2012;16:544\u201352.","journal-title":"Curr Opin Chem Biol."},{"key":"1621_CR23","doi-asserted-by":"publisher","first-page":"E4857","DOI":"10.1073\/pnas.1601700113","volume":"113","author":"W Gao","year":"2016","unstructured":"Gao W, Yang J, Liu W, Wang Y, Shao F. Site-specific phosphorylation and microtubule dynamics control Pyrin inflammasome activation. Proc Natl Acad Sci U S A. 2016;113:E4857\u201366.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"1621_CR24","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.semcdb.2011.09.001","volume":"22","author":"T Obsil","year":"2011","unstructured":"Obsil T, Obsilova V. Structural basis of 14-3-3 protein functions. Semin Cell Dev Biol. 2011;22:663\u201372.","journal-title":"Semin Cell Dev Biol."},{"key":"1621_CR25","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1002\/art.21050","volume":"52","author":"I J\u00e9ru","year":"2005","unstructured":"J\u00e9ru I, Papin S, L'Hoste S, Duquesnoy P, Cazeneuve C, Camonis J, et al. Interaction of Pyrin with 14.3.3 in an isoform-specific and phosphorylation-dependent manner regulates its translocation to the nucleus. Arthritis Rheum. 2005;52:1848\u201357.","journal-title":"Arthritis Rheum."},{"key":"1621_CR26","doi-asserted-by":"publisher","first-page":"332ra45","DOI":"10.1126\/scitranslmed.aaf1471","volume":"8","author":"SL Masters","year":"2016","unstructured":"Masters SL, Lagou V, J\u00e9ru I, Baker PJ, Van Eyck L, Parry DA, et al. Familial autoinflammation with neutrophilic dermatosis reveals a regulatory mechanism of Pyrin activation. Sci Transl Med. 2016;8:332ra45.","journal-title":"Sci Transl Med."},{"key":"1621_CR27","first-page":"485108","volume":"23","author":"HS Malik","year":"2022","unstructured":"Malik HS, Magnotti F, Loeven NA, Delgado JM, Kettenbach AN, Henry T, et al. Phosphoprotein phosphatase activity positively regulates oligomeric Pyrin to trigger inflammasome assembly in phagocytes. bioRxiv. 2022;23:485108.","journal-title":"bioRxiv."},{"key":"1621_CR28","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/rheumatology\/kex373","volume":"57","author":"Y Jamilloux","year":"2018","unstructured":"Jamilloux Y, Lefeuvre L, Magnotti F, Martin A, Benezech S, Allatif O, et al. Familial Mediterranean fever mutations are hypermorphic mutations that specifically decrease the activation threshold of the Pyrin inflammasome. Rheumatology (Oxford). 2018;57:100\u201311.","journal-title":"Rheumatology (Oxford)."},{"key":"1621_CR29","doi-asserted-by":"publisher","first-page":"111472","DOI":"10.1016\/j.celrep.2022.111472","volume":"41","author":"F Magnotti","year":"2022","unstructured":"Magnotti F, Chirita D, Dalmon S, Martin A, Bronnec P, Sousa J, et al. Steroid hormone catabolites activate the Pyrin inflammasome through a non-canonical mechanism. Cell Rep. 2022;41:111472.","journal-title":"Cell Rep."},{"key":"1621_CR30","doi-asserted-by":"publisher","first-page":"39320","DOI":"10.1074\/jbc.M104730200","volume":"276","author":"N Richards","year":"2001","unstructured":"Richards N, Schaner P, Diaz A, Stuckey J, Shelden E, Wadhwa A, et al. Interaction between Pyrin and the apoptotic speck protein (ASC) modulates ASC-induced apoptosis. J Biol Chem. 2001;276:39320\u20139.","journal-title":"J Biol Chem."},{"key":"1621_CR31","doi-asserted-by":"publisher","first-page":"604206","DOI":"10.3389\/fimmu.2020.604206","volume":"11","author":"R Papa","year":"2020","unstructured":"Papa R, Penco F, Volpi S, Gattorno M. Actin remodeling defects leading to autoinflammation and immune dysregulation. Front Immunol. 2020;11:604206.","journal-title":"Front Immunol."},{"key":"1621_CR32","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.mib.2020.01.005","volume":"54","author":"NA Loeven","year":"2020","unstructured":"Loeven NA, Medici NP, Bliska JB. The Pyrin inflammasome in host-microbe interactions. Curr Opin Microbiol. 2020;54:77\u201386.","journal-title":"Curr Opin Microbiol."},{"key":"1621_CR33","doi-asserted-by":"publisher","first-page":"e6147","DOI":"10.1371\/journal.pone.0006147","volume":"4","author":"AL Waite","year":"2009","unstructured":"Waite AL, Schaner P, Richards N, Balci-Peynircioglu B, Masters SL, Brydges SD, et al. Pyrin modulates the intracellular distribution of PSTPIP1. PLoS ONE. 2009;4:e6147.","journal-title":"PLoS ONE."},{"key":"1621_CR34","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1182\/blood.V98.3.851","volume":"98","author":"E Mansfield","year":"2001","unstructured":"Mansfield E, Chae JJ, Komarow HD, Brotz TM, Frucht DM, Aksentijevich I, et al. The familial Mediterranean fever protein, pyrin, associates with microtubules and colocalizes with actin filaments. Blood. 2001;98:851\u20139.","journal-title":"Blood."},{"key":"1621_CR35","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.molcel.2007.08.029","volume":"28","author":"JW Yu","year":"2007","unstructured":"Yu JW, Fernandes-Alnemri T, Datta P, Wu J, Juliana C, Solorzano L, et al. Pyrin activates the ASC pyroptosome in response to engagement by autoinflammatory PSTPIP1 mutants. Mol Cell. 2007;28:214\u201327.","journal-title":"Mol Cell."},{"key":"1621_CR36","doi-asserted-by":"publisher","first-page":"13501","DOI":"10.1073\/pnas.2135380100","volume":"100","author":"NG Shoham","year":"2003","unstructured":"Shoham NG, Centola M, Mansfield E, Hull KM, Wood G, Wise CA, et al. Pyrin binds the PSTPIP1\/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc Natl Acad Sci U S A. 2003;100:13501\u20136.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"1621_CR37","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s43141-022-00300-z","volume":"20","author":"AG Fayez","year":"2022","unstructured":"Fayez AG, Eldeen GN, Zarouk WA, Hamed K, Ramadan A, Foda BM, et al. Dynamic disequilibrium-based pathogenicity model in mutated pyrin\u2019s B30.2 domain-Casp1\/p20 complex. J Genet Eng Biotechnol. 2022;20:31.","journal-title":"J Genet Eng Biotechnol."},{"key":"1621_CR38","doi-asserted-by":"publisher","first-page":"9982","DOI":"10.1073\/pnas.0602081103","volume":"103","author":"JJ Chae","year":"2006","unstructured":"Chae JJ, Wood G, Masters SL, Richard K, Park G, Smith BJ, et al. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1\u03b2 production. Proc Nat Acad Sci. 2006;103:9982\u20137.","journal-title":"Proc Nat Acad Sci."},{"key":"1621_CR39","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1146\/annurev.immunol.25.022106.141627","volume":"27","author":"SL Masters","year":"2009","unstructured":"Masters SL, Simon A, Aksentijevich I, Kastner DL. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*). Annu Rev Immunol. 2009;27:621\u201368.","journal-title":"Annu Rev Immunol."},{"key":"1621_CR40","doi-asserted-by":"publisher","first-page":"23613","DOI":"10.1038\/s41598-021-03073-6","volume":"11","author":"S Samukawa","year":"2021","unstructured":"Samukawa S, Yoshimi R, Kirino Y, Nakajima H. The PRY\/SPRY domain of pyrin\/TRIM20 interacts with \u03b2(2)-microglobulin to promote inflammasome formation. Sci Rep. 2021;11:23613.","journal-title":"Sci Rep."},{"key":"1621_CR41","doi-asserted-by":"publisher","first-page":"6154","DOI":"10.4049\/jimmunol.171.11.6154","volume":"171","author":"C Stehlik","year":"2003","unstructured":"Stehlik C, Lee SH, Dorfleutner A, Stassinopoulos A, Sagara J, Reed JC. Apoptosis-associated speck-like protein containing a caspase recruitment domain is a regulator of procaspase-1 activation. J Immunol. 2003;171:6154\u201363.","journal-title":"J Immunol."},{"key":"1621_CR42","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1084\/jem.20172222","volume":"215","author":"D Boucher","year":"2018","unstructured":"Boucher D, Monteleone M, Coll RC, Chen KW, Ross CM, Teo JL, et al. Caspase-1 self-cleavage is an intrinsic mechanism to terminate inflammasome activity. J Exp Med. 2018;215:827\u201340.","journal-title":"J Exp Med."},{"key":"1621_CR43","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/nrrheum.2013.174","volume":"10","author":"S Ozen","year":"2014","unstructured":"Ozen S, Bilginer Y. A clinical guide to autoinflammatory diseases: familial Mediterranean fever and next-of-kin. Nat Rev Rheumatol. 2014;10:135\u201347.","journal-title":"Nat Rev Rheumatol."},{"key":"1621_CR44","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.berh.2018.09.003","volume":"32","author":"S \u00d6zen","year":"2018","unstructured":"\u00d6zen S. Update on the epidemiology and disease outcome of familial Mediterranean fever. Best Pract Res Clin Rheumatol. 2018;32:254\u201360.","journal-title":"Best Pract Res Clin Rheumatol."},{"key":"1621_CR45","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.berh.2017.12.001","volume":"31","author":"HJ Lachmann","year":"2017","unstructured":"Lachmann HJ. Periodic fever syndromes. Best Pract Res Clin Rheumatol. 2017;31:596\u2013609.","journal-title":"Best Pract Res Clin Rheumatol."},{"key":"1621_CR46","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1007\/s11739-021-02912-8","volume":"17","author":"O Aydin","year":"2022","unstructured":"Aydin O, Egeli BH, Ozdogan H, Ugurlu S. Late-onset familial Mediterranean fever: single-center experience and literature review. Intern Emerg Med. 2022;17:1301\u20136.","journal-title":"Intern Emerg Med."},{"key":"1621_CR47","doi-asserted-by":"publisher","first-page":"e68431","DOI":"10.1371\/journal.pone.0068431","volume":"8","author":"I J\u00e9ru","year":"2013","unstructured":"J\u00e9ru I, Hentgen V, Cochet E, Duquesnoy P, Le Borgne G, Grimprel E, et al. The risk of familial Mediterranean fever in MEFV heterozygotes: a statistical approach. PLoS One. 2013;8:e68431.","journal-title":"PLoS One."},{"key":"1621_CR48","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s10238-005-0071-6","volume":"5","author":"JC van der Hilst","year":"2005","unstructured":"van der Hilst JC, Simon A, Drenth JP. Hereditary periodic fever and reactive amyloidosis. Clin Exp Med. 2005;5:87\u201398.","journal-title":"Clin Exp Med."},{"key":"1621_CR49","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/(SICI)1096-8628(20000605)92:4<241::AID-AJMG3>3.0.CO;2-G","volume":"92","author":"C Dod\u00e9","year":"2000","unstructured":"Dod\u00e9 C, P\u00eacheux C, Cazeneuve C, Cattan D, Dervichian M, Goossens M, et al. Mutations in the MEFV gene in a large series of patients with a clinical diagnosis of familial Mediterranean fever. Am J Med Genet. 2000;92:241\u20136.","journal-title":"Am J Med Genet"},{"key":"1621_CR50","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1093\/rheumatology\/kei279","volume":"45","author":"HJ Lachmann","year":"2006","unstructured":"Lachmann HJ, Seng\u00fcl B, Yavuz\u015fen TU, Booth DR, Booth SE, Bybee A, et al. Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology (Oxford). 2006;45:746\u201350.","journal-title":"Rheumatology (Oxford)."},{"key":"1621_CR51","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/ced.15027","volume":"47","author":"C O\u2019Connor","year":"2022","unstructured":"O\u2019Connor C, Kiely L, Heffron C, Ryan J, Bennett M. PAPA-like syndrome with heterozygous mutation in the MEFV gene. Clin Exp Dermatol. 2022;47:642\u20135.","journal-title":"Clin Exp Dermatol."},{"key":"1621_CR52","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1093\/ibd\/izab139","volume":"27","author":"B Bader-Meunier","year":"2021","unstructured":"Bader-Meunier B, Martins AL, Charbit-Henrion F, Meinzer U, Belot A, Cuisset L, et al. Mevalonate kinase deficiency: a cause of severe very-early-onset inflammatory bowel disease. Inflamm Bowel Dis. 2021;27:1853\u20137.","journal-title":"Inflamm Bowel Dis."},{"key":"1621_CR53","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1002\/jimd.12412","volume":"44","author":"H Brennenstuhl","year":"2021","unstructured":"Brennenstuhl H, Nashawi M, Schr\u00f6ter J, Baronio F, Beedgen L, Gleich F, et al. Phenotypic diversity, disease progression, and pathogenicity of MVK missense variants in mevalonic aciduria. J Inherit Metab Dis. 2021;44:1272\u201387.","journal-title":"J Inherit Metab Dis."},{"key":"1621_CR54","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ymgme.2022.04.006","volume":"136","author":"I Elhani","year":"2022","unstructured":"Elhani I, Hentgen V, Grateau G, Georgin-Lavialle S. Neurological manifestations in mevalonate kinase deficiency: a systematic review. Mol Genet Metab. 2022;136:85\u201393.","journal-title":"Mol Genet Metab."},{"key":"1621_CR55","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1097\/MD.0b013e318190cfb7","volume":"87","author":"JCH van der Hilst","year":"2008","unstructured":"van der Hilst JCH, Bodar EJ, Barron KS, Frenkel J, Drenth JPH, van der Meer JWM, et al. Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome. Medicine (Baltimore). 2008;87:301\u201310.","journal-title":"Medicine (Baltimore)."},{"key":"1621_CR56","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s11926-010-0086-1","volume":"12","author":"JC van der Hilst","year":"2010","unstructured":"van der Hilst JC, Frenkel J. Hyperimmunoglobulin D syndrome in childhood. Curr Rheumatol Rep. 2010;12:101\u20137.","journal-title":"Curr Rheumatol Rep."},{"key":"1621_CR57","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/9691","volume":"22","author":"SM Houten","year":"1999","unstructured":"Houten SM, Kuis W, Duran M, De Koning TJ, Van Royen-Kerkhof A, Romeijn GJ, et al. Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinaemia D and periodic fever syndrome. Nat Gen. 1999;22:175\u20137.","journal-title":"Nat Gen."},{"key":"1621_CR58","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/9696","volume":"22","author":"JPH Drenth","year":"1999","unstructured":"Drenth JPH, Cuisset L, Grateau G, Vasseur C, Van De Velde-Visser SD, De Jong JGN, et al. Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. Nat Gen. 1999;22:178\u201381.","journal-title":"Nat Gen."},{"key":"1621_CR59","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1161\/01.RES.0000196564.18314.23","volume":"97","author":"Y Rikitake","year":"2005","unstructured":"Rikitake Y, Liao JK. Rho GTPases, statins, and nitric oxide. Circ Res. 2005;97:1232\u20135.","journal-title":"Circ Res."},{"key":"1621_CR60","doi-asserted-by":"publisher","first-page":"5436","DOI":"10.1093\/rheumatology\/keab221","volume":"60","author":"E Van Nieuwenhove","year":"2021","unstructured":"Van Nieuwenhove E, De Langhe E, Dooley J, Van Den Oord J, Shahrooei M, Parvaneh N, et al. Phenotypic analysis of pyrin-associated autoinflammation with neutrophilic dermatosis patients during treatment. Rheumatology (Oxford). 2021;60:5436\u201346.","journal-title":"Rheumatology (Oxford)."},{"key":"1621_CR61","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1136\/annrheumdis-2017-211473","volume":"76","author":"F Moghaddas","year":"2017","unstructured":"Moghaddas F, Llamas R, De Nardo D, Martinez-Banaclocha H, Martinez-Garcia JJ, Mesa-Del-Castillo P, et al. A novel pyrin-associated autoinflammation with neutrophilic dermatosis mutation further defines 14-3-3 binding of Pyrin and distinction to Familial Mediterranean Fever. Ann Rheum Dis. 2017;76:2085\u201394.","journal-title":"Ann Rheum Dis."},{"key":"1621_CR62","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/art.41976","volume":"74","author":"DL Stone","year":"2022","unstructured":"Stone DL, Ombrello A, Arostegui JI, Schneider C, Dang V, de Jesus A, et al. Excess serum interleukin-18 distinguishes patients with pathogenic mutations in PSTPIP1. Arthritis Rheumatol. 2022;74:353\u20137.","journal-title":"Arthritis Rheumatol."},{"key":"1621_CR63","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.jaci.2015.04.016","volume":"136","author":"D Holzinger","year":"2015","unstructured":"Holzinger D, Fassl SK, de Jager W, Lohse P, R\u00f6hrig UF, Gattorno M, et al. Single amino acid charge switch defines clinically distinct proline-serine-threonine phosphatase-interacting protein 1 (PSTPIP1)-associated inflammatory diseases. J Allergy Clin Immunol. 2015;136:1337\u201345.","journal-title":"J Allergy Clin Immunol."},{"key":"1621_CR64","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jaci.2020.11.043","volume":"148","author":"A Laberko","year":"2021","unstructured":"Laberko A, Burlakov V, Maier S, Abinun M, Skinner R, Kozlova A, et al. HSCT is effective in patients with PSTPIP1-associated myeloid-related proteinemia inflammatory (PAMI) syndrome. J Allergy Clin Immunol. 2021;148:250\u20135.e1.","journal-title":"J Allergy Clin Immunol."},{"key":"1621_CR65","first-page":"S113","volume":"35","author":"E Belelli","year":"2017","unstructured":"Belelli E, Passarelli C, Pardeo M, Holzinger D, De Benedetti F, Insalaco A. Case report haematological involvement associated with a mild autoinflammatory phenotype, in two patients carrying the E250K mutation of PSTPIP1. Clin Exp Rheumatol. 2017;35:S113\u2013S5.","journal-title":"Clin Exp Rheumatol."},{"issue":"19","key":"1621_CR66","doi-asserted-by":"publisher","first-page":"e172975","DOI":"10.1172\/jci.insight.172975","volume":"8","author":"Q Wang","year":"2023","unstructured":"Wang Q, Jin T, Jian S, Han X, Song H, Zhou Q, Yu X. A dominant pathogenic MEFV mutation causes atypical pyrin-associated periodic syndromes. JCI Insight. 2023;8(19):e172975. https:\/\/doi.org\/10.1172\/jci.insight.172975","journal-title":"JCI Insight."},{"key":"1621_CR67","doi-asserted-by":"publisher","first-page":"659","DOI":"10.2174\/1381612824666180123110042","volume":"24","author":"C Angelidis","year":"2018","unstructured":"Angelidis C, Kotsialou Z, Kossyvakis C, Vrettou AR, Zacharoulis A, Kolokathis F, et al. Colchicine pharmacokinetics and mechanism of action. Curr Pharm Des. 2018;24:659\u201363.","journal-title":"Curr Pharm Des."},{"key":"1621_CR68","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/bjd.15896","volume":"178","author":"B Dasgeb","year":"2018","unstructured":"Dasgeb B, Kornreich D, McGuinn K, Okon L, Brownell I, Sackett DL. Colchicine: an ancient drug with novel applications. Br J Dermatol. 2018;178:350\u20136.","journal-title":"Br J Dermatol."},{"key":"1621_CR69","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1056\/NEJM197410312911803","volume":"291","author":"D Zemer","year":"1974","unstructured":"Zemer D, Revach M, Pras M, Modan B, Schor S, Sohar E, et al. A controlled trial of colchicine in preventing attacks of familial mediterranean fever. N Engl J Med. 1974;291:932\u20134.","journal-title":"N Engl J Med."},{"key":"1621_CR70","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1056\/NEJM197212212872514","volume":"287","author":"SE Goldfinger","year":"1972","unstructured":"Goldfinger SE. Colchicine for familial Mediterranean fever. N Engl J Med. 1972;287:1302.","journal-title":"N Engl J Med."},{"key":"1621_CR71","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1056\/NEJM197410312911804","volume":"291","author":"CA Dinarello","year":"1974","unstructured":"Dinarello CA, Wolff SM, Goldfinger SE, Dale DC, Alling DW. Colchicine therapy for familial Mediterranean fever. A double-blind trial. N Engl J Med. 1974;291:934\u20137.","journal-title":"N Engl J Med."},{"key":"1621_CR72","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1053\/S0049-0172(03)00137-9","volume":"33","author":"M Lidar","year":"2004","unstructured":"Lidar M, Scherrmann JM, Shinar Y, Chetrit A, Niel E, Gershoni-Baruch R, et al. Colchicine nonresponsiveness in familial Mediterranean fever: clinical, genetic, pharmacokinetic, and socioeconomic characterization. Semin Arthritis Rheum. 2004;33:273\u201382.","journal-title":"Semin Arthritis Rheum."},{"key":"1621_CR73","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.semarthrit.2017.03.006","volume":"47","author":"S Ozen","year":"2017","unstructured":"Ozen S, Kone-Paut I, G\u00fcl A. Colchicine resistance and intolerance in familial Mediterranean fever: definition, causes, and alternative treatments. Semin Arthritis Rheum. 2017;47:115\u201320.","journal-title":"Semin Arthritis Rheum."},{"key":"1621_CR74","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/med.20097","volume":"28","author":"B Bhattacharyya","year":"2008","unstructured":"Bhattacharyya B, Panda D, Gupta S, Banerjee M. Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin. Med Res Rev. 2008;28:155\u201383.","journal-title":"Med Res Rev."},{"key":"1621_CR75","doi-asserted-by":"publisher","first-page":"3536","DOI":"10.1002\/jcb.24231","volume":"113","author":"EZ Taskiran","year":"2012","unstructured":"Taskiran EZ, Cetinkaya A, Balci-Peynircioglu B, Akkaya YZ, Yilmaz E. The effect of colchicine on Pyrin and Pyrin interacting proteins. J Cell Biochem. 2012;113:3536\u201346.","journal-title":"J Cell Biochem."},{"key":"1621_CR76","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/ncb773","volume":"4","author":"M Krendel","year":"2002","unstructured":"Krendel M, Zenke FT, Bokoch GM. Nucleotide exchange factor GEF-H1 mediates cross-talk between microtubules and the actin cytoskeleton. Nat Cell Biol. 2002;4:294\u2013301.","journal-title":"Nat Cell Biol."},{"key":"1621_CR77","doi-asserted-by":"publisher","first-page":"i4","DOI":"10.1093\/rheumatology\/kex453","volume":"57","author":"A Slobodnick","year":"2018","unstructured":"Slobodnick A, Shah B, Krasnokutsky S, Pillinger MH. Update on colchicine, 2017. Rheumatology (Oxford). 2018;57:i4\u2013i11.","journal-title":"Rheumatology (Oxford)."},{"key":"1621_CR78","first-page":"75","volume":"10","author":"J van der Hilst","year":"2016","unstructured":"van der Hilst J, Moutschen M, Messiaen PE, Lauwerys BR, Vanderschueren S. Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature. Biologics. 2016;10:75\u201380.","journal-title":"Biologics."},{"key":"1621_CR79","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2147\/JIR.S206204","volume":"13","author":"M Kacar","year":"2020","unstructured":"Kacar M, Savic S, van der Hilst JCH. The efficacy, safety and tolerability of canakinumab in the treatment of familial mediterranean fever: a systematic review of the literature. J Inflamm Res. 2020;13:141\u20139.","journal-title":"J Inflamm Res."},{"key":"1621_CR80","first-page":"260","volume":"63","author":"EJ Bodar","year":"2005","unstructured":"Bodar EJ, van der Hilst JC, Drenth JP, van der Meer JW, Simon A. Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model. Neth J Med. 2005;63:260\u20134.","journal-title":"Neth J Med."},{"key":"1621_CR81","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1111\/j.1365-2133.2009.09404.x","volume":"161","author":"M Brenner","year":"2009","unstructured":"Brenner M, Ruzicka T, Plewig G, Thomas P, Herzer P. Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br J Dermatol. 2009;161:1199\u2013201.","journal-title":"Br J Dermatol."},{"key":"1621_CR82","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1056\/NEJMoa1706314","volume":"378","author":"F De Benedetti","year":"2018","unstructured":"De Benedetti F, Gattorno M, Anton J, Ben-Chetrit E, Frenkel J, Hoffman HM, et al. Canakinumab for the treatment of autoinflammatory recurrent fever syndromes. N Engl J Med. 2018;378:1908\u201319.","journal-title":"N Engl J Med."},{"key":"1621_CR83","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1136\/annrheumdis-2015-208690","volume":"75","author":"S Ozen","year":"2016","unstructured":"Ozen S, Demirkaya E, Erer B, Livneh A, Ben-Chetrit E, Giancane G, et al. EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis. 2016;75:644\u201351.","journal-title":"Ann Rheum Dis."},{"key":"1621_CR84","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1083\/jcb.119.3.617","volume":"119","author":"P Adamson","year":"1992","unstructured":"Adamson P, Paterson HF, Hall A. Intracellular localization of the P21rho proteins. J Cell Biol. 1992;119:617\u201327.","journal-title":"J Cell Biol."},{"key":"1621_CR85","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.21873\/invivo.12047","volume":"34","author":"A Miyawaki","year":"2020","unstructured":"Miyawaki A, Rojasawasthien T, Hitomi S, Aoki Y, Urata M, Inoue A, et al. Oral administration of geranylgeraniol rescues denervation-induced muscle atrophy via suppression of atrogin-1. In Vivo. 2020;34:2345\u201351.","journal-title":"In Vivo."},{"key":"1621_CR86","doi-asserted-by":"publisher","first-page":"104975","DOI":"10.1016\/j.yrtph.2021.104975","volume":"124","author":"K Preece","year":"2021","unstructured":"Preece K, Gl\u00e1vits R, Foster JR, Murbach T, Endres JR, Hirka G, et al. A toxicological evaluation of geranylgeraniol. Regul Toxicol Pharmacol. 2021;124:104975.","journal-title":"Regul Toxicol Pharmacol."},{"key":"1621_CR87","doi-asserted-by":"publisher","first-page":"5736","DOI":"10.1074\/jbc.M206564200","volume":"278","author":"SM Houten","year":"2003","unstructured":"Houten SM, Schneiders MS, Wanders RJ, Waterham HR. Regulation of isoprenoid\/cholesterol biosynthesis in cells from mevalonate kinase-deficient patients. J Biol Chem. 2003;278:5736\u201343.","journal-title":"J Biol Chem."},{"key":"1621_CR88","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.trsl.2019.08.004","volume":"215","author":"JC Irwin","year":"2020","unstructured":"Irwin JC, Fenning AS, Vella RK. Geranylgeraniol prevents statin-induced skeletal muscle fatigue without causing adverse effects in cardiac or vascular smooth muscle performance. Transl Res. 2020;215:17\u201330.","journal-title":"Transl Res."},{"key":"1621_CR89","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jcms.2017.11.007","volume":"46","author":"F Koneski","year":"2018","unstructured":"Koneski F, Popovic-Monevska D, Gjorgoski I, Krajoska J, Popovska M, Muratovska I, et al. In vivo effects of geranylgeraniol on the development of bisphosphonate-related osteonecrosis of the jaws. J Craniomaxillofac Surg. 2018;46:230\u20136.","journal-title":"J Craniomaxillofac Surg."},{"key":"1621_CR90","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1002\/chem.201903128","volume":"26","author":"R Wu","year":"2020","unstructured":"Wu R, Chen H, Chang N, Xu Y, Jiao J, Zhang H. Unlocking the drug potential of the bryostatin family: recent advances in product synthesis and biomedical applications. Chemistry. 2020;26:1166\u201395.","journal-title":"Chemistry."},{"key":"1621_CR91","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3109\/13880209.2013.804100","volume":"52","author":"P Koll\u00e1r","year":"2014","unstructured":"Koll\u00e1r P, Rajchard J, Balounov\u00e1 Z, Pazourek J. Marine natural products: bryostatins in preclinical and clinical studies. Pharm Biol. 2014;52:237\u201342.","journal-title":"Pharm Biol."},{"key":"1621_CR92","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1124\/jpet.106.111344","volume":"321","author":"W Wannamaker","year":"2007","unstructured":"Wannamaker W, Davies R, Namchuk M, Pollard J, Ford P, Ku G, et al. (S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme\/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1beta and IL-18. J Pharmacol Exp Ther. 2007;321:509\u201316.","journal-title":"J Pharmacol Exp Ther."},{"key":"1621_CR93","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.3389\/fimmu.2019.02538","volume":"10","author":"A Zahid","year":"2019","unstructured":"Zahid A, Li B, Kombe AJK, Jin T, Tao J. Pharmacological Inhibitors of the NLRP3 Inflammasome. Front Immunol. 2019;10:2538.","journal-title":"Front Immunol."},{"key":"1621_CR94","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/s41590-020-0669-6","volume":"21","author":"JJ Hu","year":"2020","unstructured":"Hu JJ, Liu X, Xia S, Zhang Z, Zhang Y, Zhao J, et al. FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation. Nat Immunol. 2020;21:736\u201345.","journal-title":"Nat Immunol."},{"key":"1621_CR95","doi-asserted-by":"publisher","first-page":"795078","DOI":"10.3389\/fphar.2021.795078","volume":"12","author":"W Guo","year":"2022","unstructured":"Guo W, Chen S, Li C, Xu J, Wang L. Application of disulfiram and its metabolites in treatment of inflammatory disorders. Front Pharmacol. 2022;12:795078.","journal-title":"Front Pharmacol."},{"key":"1621_CR96","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/0002-9343(90)90534-K","volume":"88","author":"C Wright","year":"1990","unstructured":"Wright C, Moore RD. Disulfiram treatment of alcoholism. Am J Med. 1990;88:647\u201355.","journal-title":"Am J Med."},{"key":"1621_CR97","first-page":"840","volume":"77","author":"C Gabay","year":"2018","unstructured":"Gabay C, Fautrel B, Rech J, Spertini F, Feist E, K\u00f6tter I, et al. Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still\u2019s disease. Annals Rheum Dis. 2018;77:840\u20137.","journal-title":"Annals Rheum Dis."},{"key":"1621_CR98","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s10875-022-01236-2","volume":"42","author":"AV Geerlinks","year":"2022","unstructured":"Geerlinks AV, Dvorak AM, Jordan MB, Schiffrin EJ, Behrens EM, Marsh R, et al. A Case of XIAP deficiency successfully managed with tadekinig alfa (rhIL-18BP). J Clin Immunol. 2022;42:901\u20133.","journal-title":"J Clin Immunol."},{"key":"1621_CR99","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1016\/j.jaci.2016.10.022","volume":"139","author":"SW Canna","year":"2017","unstructured":"Canna SW, Girard C, Malle L, de Jesus A, Romberg N, Kelsen J, et al. Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition. J Allergy Clin Immunol. 2017;139:1698\u2013701.","journal-title":"J Allergy Clin Immunol."},{"key":"1621_CR100","doi-asserted-by":"publisher","first-page":"R1264","DOI":"10.1152\/ajpregu.2001.281.4.R1264","volume":"281","author":"B Siegmund","year":"2001","unstructured":"Siegmund B, Fantuzzi G, Rieder F, Gamboni-Robertson F, Lehr H-A, Hartmann G, et al. Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-\u03b3 and TNF-\u03b1 production. Am J Physiol \u2013Reg , Integr Comp Physiol. 2001;281:R1264\u2013R73.","journal-title":"Am J Physiol \u2013Reg , Integr Comp Physiol."},{"key":"1621_CR101","unstructured":"Anti IL-18 (GSK1070806) in Behcet\u2019s disease. https:\/\/classic.clinicaltrials.gov\/show\/NCT03522662."},{"key":"1621_CR102","doi-asserted-by":"publisher","first-page":"878556","DOI":"10.3389\/fphar.2022.878556","volume":"13","author":"KY Chin","year":"2022","unstructured":"Chin KY, Ekeuku SO, Trias A. The role of geranylgeraniol in managing bisphosphonate-related osteonecrosis of the jaw. Front Pharmacol. 2022;13:878556.","journal-title":"Front Pharmacol."},{"key":"1621_CR103","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s40199-021-00401-z","volume":"29","author":"RK Singh","year":"2021","unstructured":"Singh RK, Kumar S, Tomar MS, Verma PK, Kumar A, Kumar S, et al. Putative role of natural products as protein kinase C modulator in different disease conditions. Daru. 2021;29:397\u2013414.","journal-title":"Daru."},{"key":"1621_CR104","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1527-3458.2006.00001.x","volume":"12","author":"MK Sun","year":"2006","unstructured":"Sun MK, Alkon DL. Bryostatin-1: pharmacology and therapeutic potential as a CNS drug. CNS Drug Rev. 2006;12:1\u20138.","journal-title":"CNS Drug Rev."},{"issue":"Pt 2","key":"1621_CR105","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1042\/bj3100657","volume":"310","author":"M Kitagawa","year":"1995","unstructured":"Kitagawa M, Mukai H, Shibata H, Ono Y. Purification and characterization of a fatty acid-activated protein kinase (PKN) from rat testis. Biochem J. 1995;310(Pt 2):657\u201364.","journal-title":"Biochem J."},{"key":"1621_CR106","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1093\/oxfordjournals.jbchem.a022476","volume":"126","author":"C Yoshinaga","year":"1999","unstructured":"Yoshinaga C, Mukai H, Toshimori M, Miyamoto M, Ono Y. Mutational analysis of the regulatory mechanism of PKN: the regulatory region of PKN contains an arachidonic acid-Sensitive autoinhibitory domain1. J Biochem. 1999;126:475\u201384.","journal-title":"J Biochem."},{"key":"1621_CR107","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.cellsig.2004.12.003","volume":"17","author":"WG Lim","year":"2005","unstructured":"Lim WG, Zhu Y, Wang C-H, Tan BJ, Armstrong JS, Dokland T, et al. The last five amino acid residues at the C-terminus of PRK1\/PKN is essential for full lipid responsiveness. Cellular Sign. 2005;17:1084\u201397.","journal-title":"Cellular Sign."},{"key":"1621_CR108","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12944-019-1039-y","volume":"18","author":"H Kawashima","year":"2019","unstructured":"Kawashima H. Intake of arachidonic acid-containing lipids in adult humans: dietary surveys and clinical trials. Lipids Health Dis. 2019;18:101.","journal-title":"Lipids Health Dis."},{"key":"1621_CR109","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2174\/138161207780163006","volume":"13","author":"S Cornelis","year":"2007","unstructured":"Cornelis S, Kersse K, Festjens N, Lamkanfi M, Vandenabeele P. Inflammatory caspases: targets for novel therapies. Curr Pharm Des. 2007;13:367\u201385.","journal-title":"Curr Pharm Des."},{"key":"1621_CR110","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/nature15541","volume":"526","author":"N Kayagaki","year":"2015","unstructured":"Kayagaki N, Stowe IB, Lee BL, O'Rourke K, Anderson K, Warming S, et al. Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. Nature. 2015;526:666\u201371.","journal-title":"Nature."},{"key":"1621_CR111","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1038\/cr.2015.139","volume":"25","author":"WT He","year":"2015","unstructured":"He WT, Wan H, Hu L, Chen P, Wang X, Huang Z, et al. Gasdermin D is an executor of pyroptosis and required for interleukin-1\u03b2 secretion. Cell Res. 2015;25:1285\u201398.","journal-title":"Cell Res"},{"key":"1621_CR112","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/nature15514","volume":"526","author":"J Shi","year":"2015","unstructured":"Shi J, Zhao Y, Wang K, Shi X, Wang Y, Huang H, et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature. 2015;526:660\u20135.","journal-title":"Nature."},{"key":"1621_CR113","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S1097-2765(02)00599-3","volume":"10","author":"F Martinon","year":"2002","unstructured":"Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell. 2002;10:417\u201326.","journal-title":"Mol Cell."},{"key":"1621_CR114","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/j.immuni.2019.05.020","volume":"50","author":"N Van Opdenbosch","year":"2019","unstructured":"Van Opdenbosch N, Lamkanfi M. Caspases in cell death, inflammation, and disease. Immunity. 2019;50:1352\u201364.","journal-title":"Immunity."},{"key":"1621_CR115","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1084\/jem.20172060","volume":"215","author":"A Kanneganti","year":"2018","unstructured":"Kanneganti A, Malireddi RKS, Saavedra PHV, Vande Walle L, Van Gorp H, Kambara H, et al. GSDMD is critical for autoinflammatory pathology in a mouse model of Familial Mediterranean Fever. J Exp Med. 2018;215:1519\u201329.","journal-title":"J Exp Med."},{"issue":"2","key":"1621_CR116","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jcms.2017.11.007","volume":"46","author":"F Koneski","year":"2018","unstructured":"Koneski F, Popovic-Monevska D, Gjorgoski I, Krajoska J, Popovska M, Muratovska I, Velickovski B, Petrushevska G, Popovski V. In vivo effects of geranylgeraniol on the development of bisphosphonate-related osteonecrosis of the jaws. J Craniomaxillofac Surg. 2018;46(2):230\u20136. https:\/\/doi.org\/10.1016\/j.jcms.2017.11.007.","journal-title":"J Craniomaxillofac Surg."},{"key":"1621_CR117","doi-asserted-by":"publisher","first-page":"893912","DOI":"10.3389\/fimmu.2022.893912","volume":"13","author":"Z Li","year":"2022","unstructured":"Li Z, Ji S, Jiang ML, Xu Y, Zhang CJ. The regulation and modification of GSDMD signaling in diseases. Front Immunol. 2022;13:893912.","journal-title":"Front Immunol."},{"key":"1621_CR118","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3390\/toxics11010035","volume":"11","author":"W Cui","year":"2023","unstructured":"Cui W, Hull L, Zizzo A, Wang L, Lin B, Zhai M, et al. Pharmacokinetic study of rhIL-18BP and its effect on radiation-induced cytokine changes in mouse serum and intestine. Toxics. 2023;11:35.","journal-title":"Toxics."},{"key":"1621_CR119","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/nm.2717","volume":"18","author":"SL Doyle","year":"2012","unstructured":"Doyle SL, Campbell M, Ozaki E, Salomon RG, Mori A, Kenna PF, et al. NLRP3 has a protective role in age-related macular degeneration through the induction of IL-18 by drusen components. Nat Med. 2012;18:791\u20138.","journal-title":"Nat Med."},{"key":"1621_CR120","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1126\/science.175.4025.949","volume":"175","author":"T Friedmann","year":"1972","unstructured":"Friedmann T, Roblin R. Gene therapy for human genetic disease? Proposals for genetic manipulation in humans raise difficult scientific and ethical problems. Science. 1972;175:949\u201355.","journal-title":"Science."},{"issue":"23","key":"1621_CR121","doi-asserted-by":"publisher","first-page":"00164","DOI":"10.1016\/j.jgg.2023.08.001","volume":"S1673\u20138527","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Wu ZY. Gene therapy for monogenic disorders: challenges, strategies, and perspectives. J Genet Genomics. 2023;S1673\u20138527(23):00164\u20139. https:\/\/doi.org\/10.1016\/j.jgg.2023.08.001.","journal-title":"J Genet Genomics."},{"key":"1621_CR122","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. New England J Med. 2017;377:1713\u201322.","journal-title":"New England J Med."},{"key":"1621_CR123","doi-asserted-by":"publisher","first-page":"eadg6518","DOI":"10.1126\/science.adg6518","volume":"380","author":"M Arbab","year":"2023","unstructured":"Arbab M, Matuszek Z, Kray KM, Du A, Newby GA, Blatnik AJ, et al. Base editing rescue of spinal muscular atrophy in cells and in mice. Science. 2023;380:eadg6518.","journal-title":"Science."},{"key":"1621_CR124","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/35888","volume":"391","author":"A Fire","year":"1998","unstructured":"Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391:806\u201311.","journal-title":"Nature."},{"key":"1621_CR125","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","volume":"5","author":"B Hu","year":"2020","unstructured":"Hu B, Zhong L, Weng Y, Peng L, Huang Y, Zhao Y, et al. Therapeutic siRNA: state of the art. Sign Trans Target Ther. 2020;5:101.","journal-title":"Sign Trans Target Ther."},{"key":"1621_CR126","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.biotechadv.2019.04.012","volume":"37","author":"Y Weng","year":"2019","unstructured":"Weng Y, Xiao H, Zhang J, Liang X-J, Huang Y. RNAi therapeutic and its innovative biotechnological evolution. Biotechnol Adv. 2019;37:801\u201325.","journal-title":"Biotechnol Adv."},{"key":"1621_CR127","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.immuni.2011.02.020","volume":"34","author":"JJ Chae","year":"2011","unstructured":"Chae JJ, Cho YH, Lee GS, Cheng J, Liu PP, Feigenbaum L, et al. Gain-of-function Pyrin mutations induce NLRP3 protein-independent interleukin-1\u03b2 activation and severe autoinflammation in mice. Immunity. 2011;34:755\u201368.","journal-title":"Immunity."}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-023-01621-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10875-023-01621-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-023-01621-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T05:18:56Z","timestamp":1706678336000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10875-023-01621-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,22]]},"references-count":127,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["1621"],"URL":"https:\/\/doi.org\/10.1007\/s10875-023-01621-5","relation":{},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"value":"0271-9142","type":"print"},{"value":"1573-2592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,22]]},"assertion":[{"value":"28 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"8"}}